Summit Therapeutics Ownership | Who Owns Summit Therapeutics?

Overview ForecastFinancials Chart Transcripts

Summit Therapeutics Ownership Summary

Summit Therapeutics is owned by 3.19% institutional investors, 82.64% insiders, and 14.17% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 4.87% of SMMT shares. T. Rowe Price Health Sciences is the top mutual fund, with 0.80% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Summit Therapeutics	3.19%	82.64%	14.17%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	36.39M	4.87%	$689.97M
Vanguard group	11.18M	1.50%	$195.49M
Fmr	10.85M	1.45%	$205.78M
Blackrock funding, inc. /de	9.65M	1.29%	$183.04M
Blackrock	7.90M	1.13%	$61.61M
Price t rowe associates inc /md/	8.28M	1.11%	$156.95M
State street	7.03M	0.94%	$133.25M
Ubs group	3.68M	0.49%	$69.78M
Geode capital management	3.32M	0.44%	$62.89M
D. e. shaw	2.24M	0.30%	$42.51M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Apeiron capital	1.31M	23.21%	$24.82B
Superstring capital management lp	892.87K	12.09%	$16.93M
Baker bros. advisors lp	36.39M	3.96%	$689.97M
Cutter capital management, lp	400.00K	3.36%	$7.72M
Sectoral asset management	69.61K	1.16%	$1.40M
Rock springs capital management lp	710.00K	0.79%	$13.46M
Qvt financial lp	360.52K	0.50%	$6.84M
Tang capital management	550.00K	0.44%	$11.36M
Griffin asset management	191.87K	0.41%	$3.64M
Wealth management partners	63.78K	0.35%	$1.21M

Top Buyers

Holder	Shares	% Assets	Change
Ubs group	3.68M	0.01%	2.81M
D. e. shaw	2.24M	0.03%	1.83M
Norges bank	1.37M	0.00%	1.37M
Vanguard fiduciary trust	934.39K	0.00%	934.39K
Superstring capital management lp	892.87K	12.09%	892.87K

Top Sellers

Holder	Shares	% Assets	Change
Fmr	10.85M	0.01%	-2.51M
Citadel advisors	441.74K	0.00%	-2.03M
Blackrock	7.90M	0.00%	-1.92M
Polymer capital management (hk)	133.03K	0.22%	-1.29M
Price t rowe associates inc /md/	8.28M	0.02%	-1.09M

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	1.37M	0.00%	1.37M	$24.03M
Vanguard fiduciary trust	934.39K	0.00%	934.39K	$17.72M
Point72 asset management	784.19K	0.02%	784.19K	$14.87M
Marshall wace, llp	475.24K	0.01%	475.24K	$9.01M
Cutter capital management, lp	400.00K	3.36%	400.00K	$7.72M

Sold Out

Holder	Change
Sjs investment consulting	-1.00
Bay harbor wealth management	-2.00
Clearstead advisors	-2.00
Hfm investment advisors	-2.00
Wealthspire advisors	-10.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	104	-53.15%	23,850,252	-79.75%	3	1.27%	60	-46.43%	21	-69.12%
Dec 31, 2025	64	-75.00%	16,745,961	-83.72%	2	1.17%	29	-78.52%	20	-70.59%
Sep 30, 2025	101	-58.09%	20,268,240	-79.02%	2	1.61%	47	-63.85%	28	-59.42%
Jun 30, 2025	248	8.30%	97,673,633	-0.07%	13	7.50%	133	17.70%	70	-4.11%
Mar 31, 2025	14	-93.83%	26,286,219	-71.60%	3	2.20%	7	-95.17%	2	-94.74%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
T. Rowe Price Health Sciences	6.18M	0.80%	-850.33K
State Street® SPDR® S&P® Biotech ETF	5.42M	0.70%	-53.67K
Vanguard Total Stock Mkt Idx Inv	3.77M	0.49%	11.75K
Vanguard US Total Market Shares ETF	3.43M	0.46%	-167.64K
Fidelity Growth Compy Commingled Pl S	3.36M	0.43%	178.75K
Vanguard Small Cap Index	2.68M	0.35%	-10.84K
SPDR® S&P Biotech ETF	2.43M	0.33%	5.41K
Fidelity Growth Company Fund	2.52M	0.32%	136.50K
iShares Russell 2000 ETF	2.31M	0.31%	-
Vanguard Institutional Extnd Mkt Idx Tr	1.74M	0.22%	13.60K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 04, 2026	DUGGAN ROBERT W	Co-Chief Executive Officer	Buy	$1.46M
Jun 04, 2026	Zanganeh Mahkam	Co-Chief Executive Officer	Buy	$1.46M
Jun 04, 2026	Soni Manmeet Singh	COO and CFO	Buy	$361.50K
Jun 04, 2026	Soni Manmeet Singh	COO and CFO	Buy	$360.75K
Oct 21, 2025	Xia Yu	-	Buy	$10.00M

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	4	-
2026 Q1	-	-
2025 Q4	3	-
2025 Q3	4	-
2025 Q2	-	-

SMMT Ownership FAQ

Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 3.19%, followed by 82.64% insiders and 14.17% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 35.75%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (36.39M shares, 4.87%), Vanguard group (11.18M shares, 1.50%), and Fmr (10.85M shares, 1.45%). Together, they hold 7.82% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Apeiron capital is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 23.21% of its assets in 1.31M Summit Therapeutics shares, valued at 24.82B$.

Who is the top mutual fund holder of Summit Therapeutics shares?

T. Rowe Price Health Sciences is the top mutual fund holder of Summit Therapeutics shares, with 0.80% of its total shares outstanding invested in 6.18M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools